Lena Biosciences

Executive Summary

Lena Biosciences is a privately held life sciences company headquartered in Atlanta, GA, that specializes in engineering fit-for-purpose 3D tissue models and mechanistic assays for drug discovery and predictive toxicology. Founded in 2016, the company has developed a proprietary Perfused Organ Panel microphysiological system that enables the generation of human-relevant data, addressing a critical bottleneck in preclinical drug development. By providing innovative 3D cell culture products and services, Lena Biosciences aims to improve the predictive accuracy of drug safety and efficacy testing, reducing reliance on animal models and enabling more efficient therapeutic development. The company targets the growing demand for advanced in vitro models amid regulatory pressure to adopt non-animal methods, positioning itself as a key enabler in the cell therapy and regenerative medicine value chain. Lena Biosciences operates in the rapidly expanding organ-on-a-chip and 3D cell culture market, projected to reach over $5 billion by 2030. With its validated platform and focus on human-relevant data, the company is well-positioned to capture partnerships with pharmaceutical and biotechnology firms seeking more predictive preclinical data. Despite being at a pre-clinical stage, Lena Biosciences has the potential to become a leading provider of microphysiological systems for drug screening. Key near-term catalysts include strategic partnerships, product line expansion, and potential Series A financing to scale commercial operations.

Upcoming Catalysts (preview)

• Q3 2026Strategic partnership with top 20 pharma company60% success
• Q4 2026Launch of next-generation liver model for metabolic toxicity70% success
• H1 2027Series A funding round closure50% success